497. Safety and tolerability of 2000mg intravenous sotrovimab dose in immunocompromised participants uninfected with SARS-CoV-2 in the PROTECT-V trial

ABSTRACT:

SUBMITTER:  

PROVIDER: S-EPMC10679160 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature